China

News

BMS buys Asian rights to key growth drug Camzyos

Bristol-Myers Squibb has decided it wants complete, worldwide control of cardiovascular drug mavacamten, tipped as a future blockbuster, so it has paid $350 million to sho

News

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years,

News

AZ may spin off its Chinese business, says report

AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t

Market Access

China’s 4+7 drug procurement policy and its impact on the ph...

It is estimated that China has around 10,000 pharmaceutical companies varying in size, strategy, and technology.

News

CStone gets a win for sugemalimab in oesophageal cancer

Suzhou-based CStone Pharmaceuticals' checkpoint inhibitor sugemalimab has proved effective in a trial as a first-line therapy for oesophageal cancer, setting up a regulatory filing in China

News

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medic

BMS buys Asian rights to key growth drug Camzyos

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

AZ may spin off its Chinese business, says report

China’s 4+7 drug procurement policy and its impact on the ph...

CStone gets a win for sugemalimab in oesophageal cancer

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

LSX2026: On a therapeutic vision for ocular disease, with Al...

Using AI-driven synthetic personas to take your insights fur...

China

Editor's Picks